Highlights Newsletter 1

This newsletter presents you the following key sessions:

1. Podcast with Prof. Erika Martinelli about evidence of therapeutic effectiveness of third-line cetuximab
    rechallenge in appropriately selected patients with metastatic colorectal cancer

2. HER2 and PD-L1 co-expression in patients with HER2-positive, trastuzumab-refractory gastric or
    gastroesophageal junction cancer

3. Confirmed superiority for nivolumab-based combination therapy over chemotherapy alone in previously
    untreated patients with advanced oesophageal cancer

4. Optimizing the bevacizumab and anti-EGFR sequence in RAS wildtype metastatic colorectal cancer:
    The switch maintenance concept